Ark to restructure while it appeals against Cerepro decision

Friday 29 January 2010

Ark Therapeutics Group Plc plans to reduce its staff while it appeals against a negative opinion from the European Medicines Agency for its lead gene therapy. It is also putting a hold on a Phase 3 trial for Vitor, a treatment for cancer-related muscle wasting. 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom